Cetuximab-induced aseptic meningitis.
Feinstein
T M
TM
Head and Neck Cancer Program, University of Pittsburgh Cancer Institute and Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Gibson
M K
MK
Head and Neck Cancer Program, University of Pittsburgh Cancer Institute and Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Argiris
A
A
Head and Neck Cancer Program, University of Pittsburgh Cancer Institute and Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: argirisae@upmc.edu.
D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D000068818:Cetuximab; D003907:Dexamethasone / Q000008:administration & dosage; D004155:Diphenhydramine / Q000008:administration & dosage; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D008297:Male; D008582:Meningitis, Aseptic / Q000139:chemically induced*; D008875:Middle Aged; D011292:Premedication; D014067:Tonsillar Neoplasms / Q000188:drug therapy
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003907:Dexamethasone; D004155:Diphenhydramine; D000068818:Cetuximab